U.S. Male Infertility Market (2024 - 2030)

U.S. Male Infertility Market Size & Trends

The U.S. male infertility market was valued at USD 1.01 billion in 2023 and is expected to expand at a CAGR of 4.2% from 2024 to 2030. Increasing awareness of fertility diagnosis paired with improving success rates of assisted reproductive technology (ART) is significantly driving the market growth. A higher success rate than other medications and advancements in technology are expected to increase the demand for ART, which is likely to drive growth over the forecast period.

In 2023, U.S. accounted for over 26.0% in the global male infertility market. Increase in number of approvals & launch of innovative devices, high adoption of technologically advanced devices, and significant healthcare spending are some of the key factors supplementing this market’s growth. Furthermore, the increasing disposable income is resulting in a high adoption rate of ART. This growth is also attributed to the large number of medical institutions offering ART-based services. The government is undertaking various initiatives to remove the stigma & hesitation around ART and raise public awareness through advertising & policies, which are likely to propel market growth. For instance, in over 14 states including New York, Rhode Island, Texas, Ohio, and Montana, the state governments have mandated health insurance coverage for infertility treatments, which is fueling the market for ART treatments.

The fertility rate in the U.S. has been decreasing over the years. As per the Centers for Disease Control and Prevention (CDC) data, birth rate in the country declined significantly from 2007 to 2022, dipping from 14.3 births per 1000 people to 11.1 births. According to WHO, over 15.0% of couples in the U.S. suffer from infertility. As per statistics, around 50.0% infertility cases are related to male. More distinctively, approximately 20.0% of infertility cases are entirely due to males, with an additional 30.0% to 40.0% cases involving both males and females.

Market Concentration & Characteristics

The market growth stage is medium (CAGR: <5%) and pace of the market growth depicts an accelerating trend. Continuous efforts in R&D are being carried out for improving the success rates of treatment. Companies are investing in the development of devices for identifying the root cause and targeted treatment. Furthermore, improved safety of patient data due to standardization of regulations is expected to increase patient preference for infertility treatments.

• Introduction of advanced fertility treatments is likely to drive the U.S. male infertility market during the forecast period. Advanced innovations, including sperm preparation media & catheters by Irvine Scientific; in-vitro tubes & dishes by Thermo Fischer; three unique technologies Gavi, Geri, & Gems by Genea Biomedx; Eeva test (noninvasive system) by Merck, and a range of fertility treatments by Boston IVF are opening new growth avenues for the market.

• The market is witnessing an increasing number of merger & acquisition (M&A) activities that are being undertaken by the prominent players. Several key U.S. male infertility companies are adopting these strategies to upgrade their portfolio. For instance, in March 2022, Ro, a virtual care direct-to-consumer company acquired a sperm testing & male fertility start-up Dad, to launch Ro Sperm Kit. The sperm kit allows users for home collection of samples for storage and analysis.

• Semen analysis and sperm function tests are high-complexity tests and are regulated by the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) in the U.S. Strict compliance with standards and on-site inspections are essential. The FDA regulates drugs and devices used in IVF, followed by implementation of the Fertility Clinic Success Rate and Certification Act by CDC. Male fertility testing devices are classified under class II devices. The Centers for Medicare and Medicaid Services (CMS) is responsible for approving diagnostic tools and determining reimbursement for ART procedures.

Test Insights

The DNA fragmentation segment accounted for the largest revenue share of 21.9% in 2023. It is also expected to grow at the fastest CAGR over the forecast period. The dominance is attributable to the ability of the diagnostic techniques to provide a reliable analysis of sperm DNA integrity. Adoption of this technique is increasing in the market as sperm DNA fragmentation is a leading cause of infertility in males.

Semen analysis is an excellent method to test sperm count, morphology, motility, and pH. However, it does not give any information about the DNA integrity of sperm. Hence, a separate test is available to test DNA damage in sperm cells. DNA damage generally increases with age. Various factors such as chemicals, excessive heat, chronic prostate infection, smoking, and chemotherapy may damage the DNA in sperm. DNA fragmentation helps identify males with higher risk of infertility and to determine the treatment accordingly.

Treatment Insights

The ART and varicocele surgery segment dominated the market with a revenue share of 70.9% in 2023. It is also expected to grow at the fastest CAGR over the forecast period. The most preferred technique for treatment of male infertility is enhancing spermatogenesis with the help of hormonal therapy for a natural pregnancy, especially among males with a low sperm count.

ARTs are used to treat major factors responsible for male infertility, such as sperm autoantibodies, viral orchitis, epididymal dysfunction, accessory gland infection, and other idiopathic factors. Standardization of procedures through automation, regulatory reforms, and government funding for sperm storage are some of the contributing factors for the segment growth.

Key U.S. Male Infertility Company Insights

The market has been characterized by intense competition. Market players undertake strategies such as development of innovative technologies for diagnosis and treatment, acquisitions, and partnerships or collaborations for development and commercialization of products to remain competitive in the market. Moreover, market players are availing certification from the regulatory agencies to strengthen their position in the market.

Recent Developments

• In August 2023, Reproductive Medicine Associates (RMA) acquired Conceptions Reproductive Associates of Colorado. RMA added Colorado to its network of 25 fertility centers in New Jersey, Texas, Florida, California, Pennsylvania, and Washington.

• In July 2021, Hamilton Throne Ltd. Global provider of ART research acquired IVFTECH ApS (IVFtech) and its associated firm, K4 Technology ApS. IVFtech is dedicated to providing laminar flow workstations and huge-capacity incubators for the ART with the aid of its associated firm, K4. The transaction was worth USD 8 million.

U.S. Male Infertility Market